Biomedical Research, Science, & Technology

There is ongoing interest in understanding ways to reduce drug prices and improve patient access to prescription drugs in the U.S. The estimated savings to the U.S. healthcare system from the use of biosimilars are significant.

Providing compensation to clinical research participants to offset the costs associated with participation is often suggested as a way to improve recruitment and retention. However, relatively little is known about the landscape of compensation in clinical research.

Spending on biologics—large, complex molecules made from a living source—has been increasing over time and now represents nearly half of all U.S. prescription drug spending. Biosimilar competition for biologics is limited.

Increasing patient engagement in clinical trials offers opportunities to improve enrollment and retention in clinical trials, helping ensure interventions can be evaluated effectively and that clinical research dollars are used efficiently.

The cost of raising a family in America is high and continues to rise, with inflation rising by 23 percent between 2020 and 2025. For working families, some of the largest nondiscretionary expenses continue to be health care and child care.

We conducted a landscape analysis to understand the characteristics, impacts, and costs associated with medical device shortages during the COVID-19 pandemic in the U.S. Among health systems, nursing homes and rural hospitals were the most impacted by medical device shortages due to high demand and supply transportation issues.

The 2025-2028 Draft Action Plan for Addressing Shortages of Medical Products and Critical Foods and Strengthening the Resilience of Medical Product and Critical Food Supply Chains (“Draft Action Plan”) presents coordinated and strategic actions that the Department of Health and Human Services (“HHS,” or “Department”) plans to take from 2025 through 2028.

To understand the size and impact of costs to clinical trial participants, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) conducted an exploratory survey of 112 U.S. adults who participated in an oncology clinical trial between 2018-2024.

Biosimilars provide competition for biologics, which account for a significant and growing portion of Medicare Part B drug spending. This report evaluates the current state of biosimilar competition in Medicare Part B and explores opportunities to achieve further savings.

The U.S. supply chain for provider-administered outpatient drugs involves several entities, including drug manufacturers, wholesalers, healthcare providers (e.g., outpatient facilities, hospital pharmacies, doctor’s offices, and standalone clinics), group purchasing organizations (GPOs), payers, and beneficiaries.